Status
Completed
Phase
Phase 3
Enrollment
295
Locations
1
Results
Not posted
Publications
0
Study summary
The purpose of this study is to compare two different techniques of performing a pancreatic anastomosis; Cattell-Warren versus Blumgart to determine if a Blumgart anastomosis reduces pancreatic remnant leak, post-operative complications and overall length of hospital stay.
This is a randomised controlled, phase III, double blinded, multicentre clinical trial comparing Cattell-Warren (CWA) versus. Blumgart (BA) methods of pancreaticojejunostomy following pancreaticduodenectomy for supected malignancy of the pancreatic head. The primary objective of the trial is to establish if the Blumgart anastomosis reduces pancreatic remnant leak and in turn complications, hospital stay, cost and promote enhanced recorvery programs. 506 patients (253 patients per treatment arm) will be recruited from approximately 7 centres throughout the United Kingdom. Patients recommended for resection who provide written informed consent will be randomised to one of the following treatment arms on the day of surgery by the surgeon: Arm A: Blumgart method of panreaticojejunostomy. Arm B: CattellWarren method pf pancreaticojejunostomy. Randomisation will be undertaken intra-operatively, following pancreatic head excision, just prior to pancreatic head remnant reconstruction. Patients will be assessed post operatively on days 3 to 7 and on day of dishcharge from hospital. Patients will continue to be followed up in the outpatient setting at 3, 6 and 12 months post surgery. All laboratory and physical assessments performed will be in line standard care. Blood samples for the translational study will be taken subject to informed consent pre-operatively and post-operatively 5 days after surgery. A histological (H\&E stained) slide of the pancreatic transection margin should be taken as routine. This will be requested from each patient for central pathology review to assess the amount of fibrosis.
Interventions
PROCEDURE
1. Trans pancreatic suture "U" stich incorporating pancreatic parenchyma and jejunal serosa, left loose. 2. Pancreatic duct to jejunal mucosa sutures, inserted and tied. 3. Trans pancreatic suture "U" stich brought back through the jejuanl serosa anteriorly, tied.
PROCEDURE
1. Posterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied. 2. Pancreatic duct to jejunal mucosa sutures, inserted and tied. 3. Anterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied.
DRUG
Octrotide (100ug) to be administered on the evening before surgery and then 100ug three times daily on the day of surgery and post operative days 1 - 6.
Timeline
First posted
May 29, 2015
Study start
Apr 23, 2015
Primary completion
Jul 31, 2018
Study completion
Jan 31, 2019
Results posted
Not reported
Registry updated
Mar 13, 2025
Outcomes
Presence or absence of post-operative pancreatic fistula
Time frame · Assessed up to 3 months after surgery.
Post-operative pancreatic fistula are defined as any abnormal connection between the pancreatic duct epithelium and another epithelised surface, which contains pancreatic derived, enzyme rich fluid. This will be assessed up to 3 months following surgery on inpatient days 3-7, day of discharge (expected to be 1 - 5 weeks after surgery) and 3 month follow up.
Entry into programs of adjuvent therapy
Time frame · 3, 6 and 12 month follow up
Mortality Rate
Time frame · Death due to any cause during the study will be recorded
Rate of delayed gastric emptying
Time frame · Post operative day 3, 5, 7, and the day of discharge, which is expected to be between 1 - 5 weeks after surgery.
Rate of wound infections
Time frame · Post operative day 3, 5, 7, the day of discharge, which is expected to be between 1 - 5 weeks after surgery and 3, 6 and 12 month follow up
Rate of pulmonary infection
Time frame · The day of discharge, which is expected to be between 1 - 5 weeks after surgery and 3 month follow up.
Rate of post-operative fluid collections
Time frame · post operative days 3-7, the day of discharge, which is expected to be between 1 - 5 weeks after surgery and 3 month follow-up
Operation time
Time frame · Day of surgery
Rate of intra and post-operative bleeding
Time frame · day of surgery, post operaive day 3, 5, 7 and the day of discharge, which is expected to be between 1 - 5 weeks after surgery
Rate of re-operation
Time frame · Up to 12 months after surgery
Rate of venous thrombo-embolism
Time frame · Post operative day 3, 5, 7, the day of discharge, which is expected to be between 1 - 5 weeks after surgery, 3, 6 and 12 month follow up
Eligibility
Inclusion Criteria: * Patients undergoing an elective pancreato-duodenectomy for presumed malignancy. * Ability of the subject to understand the nature and consequences of the trial. * Ability to rovide writen informed consent. * Age 18 or greater. Exclusion Criteria: * Patients undergoing extended pancreato-duodenectomy * Left, central or total pancreatectomy. * Arterial resection or multi-visceral resection * Previous pancreatic surgery * Surgery for known chronic pancreatitis. * Recruited to any other pancreatic resection trial. * Pregnant women. * Women of childbearing potential, including women whose last menstrual period was less than one year prior to screening, unable or unwilling to use adequate contraception from time of consent up to the day of surgery.
Study locations
United Kingdom. Showing up to 24 locations stored in the fast local snapshot.
Royal Liverpool University Hospital
Liverpool, Merseyside, United Kingdom
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
National Cancer Institute (NCI) · Colorectal Neuroendocrine Tumor G1 · Gastric Neuroendocrine Tumor G1
Phase 3
Active, not recruiting
427
2026-07
Camurus AB · Gastro-enteropancreatic Neuroendocrine Tumor
Phase 3
Active, not recruiting
332
2026-07
Debiopharm International SA · Acromegaly
Phase 3
Recruiting
119
2026-07
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · ACTH · Cushing's Syndrome
Phase 2
Recruiting
80
2026-07
M.D. Anderson Cancer Center · Neuroendocrine Carcinoma · Islet Cell Carcinoma
Phase 2
Completed
67
2026-07
Columbia University · Hyperinsulinemia · Insulin Resistance
Phase 1
Recruiting
25
2026-07
Camurus AB · Acromegaly
Not applicable
Recruiting
200
2026-06
Triastek (Shanghai) Limited · Acromegaly
Phase 1
Not yet recruiting
18
2026-06
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.